Clinical trial
Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined…
NCT00290342 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00290342 |
|---|---|
| Title | Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants |
| Official title | A Multicentric Study to Compare the Immunogenicity, Safety & Reactogenicity of GSK Biologicals' DTPa-IPV Vaccine vs. Co-administration of GSK's DTPa Vaccine & Sanofi-Pasteurs' IPV Vaccine at Different Injection Sites, to Healthy Children |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Tetanus, Acellular Pertussis, Diphtheria |
| Intervention type | Biological |
| Interventions | DTPa-IPV, DTPa, IMOVAX Polio® |
| Enrollment | 458 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 23, 2007 |
| First posted | Feb 13, 2006 |
| Last update posted | Oct 29, 2018 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: